1.37
+3.01%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Quantum-Si
From its filings with the US Securities and Exchange Commission
Quantum-Si is based in Branford, Connecticut and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker QSI. The SEC classifies its business as measuring & controlling devices, nec. In the fiscal year to 31 December 2025, it reported revenue of $2.4m and a net loss of $101.3m. At that date it held total assets of $245.6m and shareholders' equity of $220.2m. By business, Product brought in 93.8% of revenue, followed by Service at 6.2%. By region, International accounted for 71.3%, followed by Domestic at 28.7%.
Quantum-Si Incorporated (including its subsidiaries, “Quantum-Si”, “QSI”, or the “Company”) was incorporated in Delaware on June 10, 2020 as HighCape Capital Acquisition Corp. (“HighCape”). The Company’s legal name became Quantum-Si Incorporated following a business combination on June 10, 2021 between the Company and Q-SI Operations Inc. (formerly Quantum-Si Incorporated) (the “Business Combination”), which was founded in 2013.
We are a life sciences company focused on proteomics research, with the mission of transforming single-molecule analysis and democratizing its use by providing researchers and clinicians access to the proteome, the set of proteins expressed within a cell. We have developed a proprietary, universal, single-molecule detection platform that we are applying to proteomics to enable next-gen protein sequencing (“NGPS”) to sequence proteins in a massively parallel fashion (rather than sequentially, one at a time), which can also be used for the study of nucleic acids. We believe in the ability to sequence proteins in a massively parallel fashion and offer a fast analysis time which provides NGPS with the potential to unlock significant biological information through improved resolution and unbiased access to the proteome at a speed and scale not available today. Traditionally, proteomic workflows to sequence proteins required days or weeks to complete. Our current platform includes our Platinum® NGPS line of instruments, Platinum Analysis Software and consumable kits for use with our Platinum line of instruments.
Quoted from its 10-K, filed 3 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 4 Sept 2020
- Employees
- 138
- Website
- quantum-si.com ↗
- Head office
- 29 BUSINESS PARK DRIVE, BRANFORD, CT, 06405
- Incorporated in
- DE
- Classification
- Measuring & Controlling Devices, NEC
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Charles KummethIndependent Non-Executive Chairman of the Board$739,315
- Mr. Jeffrey HawkinsPresident, Chief Executive Officer, Director, since 2022$4.4m
- Mr. Jeffry KeyesChief Financial Officer, Treasurer$2.0m
- Dr. Christian LaPointeGeneral Counsel, Corporate Secretary$2.1m
- Mr. Todd BennettChief Commercial Officer$1.3m
- Mr. John VieceliChief Product Officer
- Ms. Paula DowdyIndependent Director$469,148
- Ms. Ruth FattoriIndependent Director$220,000
- Mr. Amir JafriIndependent Director$202,864
- Mr. John KennyIndependent Director$212,500
- Ms. Brigid MakesIndependent Director$217,782
- Mr. Scott MendelIndependent Director$205,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 25
- Environment
- 27
- Social
- 27
- Governance
- 22
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Proprietary universal single-molecule detection platform enables Next-Generation Protein Sequencing
- Carbon automated sample preparation instrument supports diverse applications via single-use fluidics cartridge
- Platinum NGPS instrument makes single-molecule detection broadly accessible
Weaknesses
- 196 full-time employees in Branford, Connecticut
- IPO on 4 September 2020 with limited market presence
- Quantum-Si Cloud software service requires integration into cloud solutions
Opportunities
- Life Sciences Tools & Services sector growth in Health Care industry
- Expansion into protein sequencing applications for pharmaceutical research
- Collaboration with pharmaceutical companies for NGPS adoption
Threats
- Limited employee count of 196 in competitive Health Care sector
- Potential market saturation in protein sequencing technology
- Competition from established Life Sciences Tools & Services providers
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.